BioSpace News Archive

The approval was built on data from the Phase III KEYNOTE-048 clinical trial.

Denis Rebrikov indicates he plans to ask for approval from three government agencies, including Russia’s health ministry. He told Nature that could take anywhere from one month to two years.

The agreement is the outcome of preclinical research on novel CD38 targeting concepts conducted by Genmab.

The FAST Advisory Program gives chosen entrepreneurs intensive team review and coaching to fine-tune their business model, product development plans and to build a compelling commercialization strategy.

“We are honored to join with The Bill & Melinda Gates Foundation to fight tuberculosis, one of the world’s most deadly infectious diseases,” stated Werner Lanthaler, Evotec’s chief executive officer.

Five $100,000 grants are offered to researchers who will explore the potential link of an infection on Alzheimer’s disease.

CAR-T cells are T-cells that have been engineered to express a receptor (called a chimeric antigen receptor, or CAR) that recognizes a specific type of cancer cell.

Servier and Galapagos NV completed recruitment for their ROCCELLA Phase 2 trial with GLPG1972/S201086, ahead of schedule.

Heidelberg Pharma AG announced that they will present their proprietary technology for Antibody Targeted Amanitin Conjugates as potential therapeutic modality for cancer therapy at two upcoming scientific conferences.

The Dutch company Xenikos B.V. announced that the U.S. Food and Drug Administration has approved an investigational new drug application to initiate a U.S.-based clinical Phase 3 registration trial in order to test the efficacy of T-Guard for treating steroid-refractory acute graft-versus-host disease in patients following allogeneic stem cell transplantation.